Literature DB >> 3461005

Combined influences of Gm and HLA phenotypes upon multiple sclerosis susceptibility and severity.

J P Salier, R Sesboüé, C Martin-Mondière, M Daveau, P Cesaro, B Cavelier, A Coquerel, L Legrand, J M Goust, J D Degos.   

Abstract

In some Caucasian populations, multiple sclerosis (MS) susceptibility has been independently related to given alleles of HLA or Gm systems that respectively code for major histocompatibility complex class I and II antigens or immunoglobulin G heavy chains. Whether given combinations of alleles at both series of loci simultaneously influence MS susceptibility and/or severity was investigated by comparing 147 French MS patients and 226 geographically-matched healthy controls. The G2m(-23)/HLA-B35 phenotype and G1m(-1)/HLA-B7(-)/HLA-DR2 phenotype were respectively associated with significant protection against (relative risk = 0.05) and susceptibility to (relative risk = 4.3) MS. When considering MS severity, the presence of HLA-B7 antigen correlated with a more severe disease in Gm1/Gm3 heterozygous patients, but not in Gm3/Gm3 homozygous patients. Conversely, an HLA-B12-associated milder disease was restricted to Gm3/Gm3 homozygotes. These results demonstrate the combined influence on MS of genetic loci that are unlinked but immune response-associated. Combined Gm and HLA typing is very likely able to serve as a prognostic indicator in this disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3461005      PMCID: PMC423590          DOI: 10.1172/JCI112605

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

Review 2.  HL-A antigens and disease. Statistical and genetical considerations.

Authors:  A Svejgaard; C Jersild; L S Nielsen; W F Bodmer
Journal:  Tissue Antigens       Date:  1974

3.  Letter: Histocompatibility determinants in multiple sclerosis.

Authors:  L Degos; J Dausset
Journal:  Lancet       Date:  1974-02-23       Impact factor: 79.321

4.  Histocompatibility determinants in multiple sclerosis, with special reference to clinical course.

Authors:  C Jersild; T Fog; G S Hansen; M Thomsen; A Svejgaard; B Dupont
Journal:  Lancet       Date:  1973-12-01       Impact factor: 79.321

5.  Clonidine in migraine.

Authors:  P A Pollard; J Shafar; P A Knowlson; E R Tallett
Journal:  Lancet       Date:  1972-06-03       Impact factor: 79.321

6.  HL-A antigens and multiple sclerosis.

Authors:  J Bertrams; E Kuwert; U Liedtke
Journal:  Tissue Antigens       Date:  1972

7.  Serotyping for homotransplantation. 18. Refinement of microdroplet lymphocyte cytotoxicity test.

Authors:  K K Mittal; M R Mickey; D P Singal; P I Terasaki
Journal:  Transplantation       Date:  1968-11       Impact factor: 4.939

8.  Immunoglobulin G heavy chain (Gm) allotypes in multiple sclerosis.

Authors:  J P Pandey; J M Goust; J P Salier; H H Fudenberg
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

9.  Defective immunoregulation in multiple sclerosis.

Authors:  J M Goust; P M Hoffman; J Pryjma; E L Hogan; H H Fudenberg
Journal:  Ann Neurol       Date:  1980-11       Impact factor: 10.422

10.  Genetic basis of multiple sclerosis: HLA antigens, disease progression, and oligoclonal IgG in CSF.

Authors:  L Stendahl-Brodin; H Link; E Möller; E Norrby
Journal:  Acta Neurol Scand       Date:  1979-06       Impact factor: 3.209

View more
  1 in total

1.  Susceptibility to multiple sclerosis and the immunoglobulin heavy chain variable region.

Authors:  N W Wood; S J Sawcer; H F Kellar-Wood; P Holmans; D Clayton; N Robertson; D A Compston
Journal:  J Neurol       Date:  1995-10       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.